Bromine- and iodine-substituted 16α,17α-dioxolane progestins for breast tumor imaging and radiotherapy: Synthesis and receptor binding affinity

Journal of Medicinal Chemistry

Volumn 49, Issue 15, 2006, Pages 4737-4744

  Zhou, Dong ^a   Carlson, Kathryn E ^b   Katzenellenbogen, John A ^b   Welch, Michael J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; 16ALPHA,17ALPHA [1' ALPHA (5 BROMOFURYLMETHYLIDENE)DIOXYL] 21 HYDROXY 19 NORPREGN 4 ENE 3,20 DIONE; 21 FLUORO 16ALPHA,17ALPHA [1' ALPHA (5 IODOFURYLMETHYLIDENE)DIOXYL] 19 NORPREGN 4 ENE 3,20 DIONE; 21 FLUORO 16ALPHA,17ALPHA [1' BETA (4 IODOPHENYLMETHYLIDENE)DIOXYL] 19 NORPREGN 4 ENE 3,20 DIONE; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; DIAGNOSTIC IMAGING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ISOTOPE LABELING; LIPOPHILICITY; POSITRON EMISSION TOMOGRAPHY;

ANIMALS; BINDING, COMPETITIVE; BREAST NEOPLASMS; DIOXOLANES; FEMALE; NEOPLASMS, HORMONE-DEPENDENT; NORPREGNENES; PROGESTINS; RADIOLIGAND ASSAY; RATS; RECEPTORS, PROGESTERONE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33746684273     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060348q     Document Type: Article

References (55)

1. (a) Dehdashti, F.; Flanagan, F. L.; Mortimer, J. E.; Katzenellenbogen, J. A.; Welch, M. J.; Siegel, B. A. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur. J. Nucl. Med. 1999, 26, 51-56.
2. (b) Mortimer, J. E.; Dehdashti, F.; Siegel, B. A.; Trinkaus, K.; Katzenellenbogen, J. A.; Welch, M. J. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J. Clin. Oncol. 2001, 19, 2797-2803.
3. 18F]fluoro- 17β-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy. Clin. Cancer Res. 1996, 2, 933-939.
4. 18F]fluoromoxestrol in isolated hepatocytes. Nucl. Med. Boil. 1999, 26, 123-130.
5. 18F-FDG in patients with progressive, metastatic prostate cancer. J. Nucl. Med. 2004, 45, 366-373.
6. (b) Dehdashti, F.; Picus, J.; Michalski, J. M.; Dence, C. S.; Siegel, B. A.; Katzenellenbogen, J. A.; Welch, M. J. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 344-350.
7. (a) McElvany, K. D.; Welch, M. J.; Katrenellenbogen, J. A. Radiobrominated estrogen receptor-binding radiopharmaceuticals for breast tumor imaging. Nucl. Med. Biol. Adv. Proc. World Congr., 3rd. 1983, 4, 3610-3613.
8. 77Br]-bromo-11β-methoxyestradiol-17β two estrogen receptor-binding radiopharmaceuticals. Int. J. Appl. Radiat. Isot. 1982, 33, 545-551.
9. 77Br]bromo- 11β-methoxyestradiol-17β: a gamma-emitting estrogen imaging agent with high uptake and retention by target organs. J. Nucl. Med. 1982, 23, 411-419.
10. (d) Katzenellenbogen, J. A.; Senderoff, S. G.; McElvany, K. D.; O'Brien, H. A., Jr.; Welch, M. J. 16α-[bromine-77]bromoestradiol-17β: a high specific-activity, gamma-emitting tracer with uptake in rat uterus and induced mammary tumors. J. Nucl. Med. 1981, 22, 42-47.
11. 77Br] bromonorhexestrol), two gamma-emitting estrogens that show receptor-mediated uptake by target tissues in vivo. J. Med. Chem. 1982, 25, 1307-1312.
12. 77Br]bromoestradiol: dosimetry and preliminary clinical studies. J. Nucl. Med. 1982, 23, 425-430.
13. 125I]iodovinyl-19-nortestosterones: potential radioligands for androgen and progesterone receptors. Steroids 2003, 68, 1163-71.
14. (h) Downer, J. B.; Jones, L. A.; Engelbach, J. A.; Lieh, L. L.; Mao, W.; Carlson, K. E.; Katzenellenbogen, J. A.; Welch, M. J., Comparison of animal models for the evaluation of radiolabeled androgens. Nucl Med Biol 2001, 28, 613-26.
15. 125I]-iodovinyl)-19- nortestosterone: a new radioligand for the detection of androgen receptor. Steroids 1993, 58, 13-23.
16. (j) Labaree, D. C.; Hoyte, R. M.; Nazareth, L. V.; Weigel, N. L.; Hochberg, R. B. 7α-lodo and 7α-fluoro steroids as androgen receptor-mediated imaging agents. J Med Chem 1999, 42, 2021-34.
17. 125I]iodo-19-nortestosterone: a gamma-emitting photoaffinity label for the progesterone receptor. Endocrinology 1988, 122, 1923-32.
18. 125I]iodoestradiol for estrogen receptor-containing breast cancer cells. Endocrinology 1982, 110, 2177-2182.
19. (a) Bloomer, W. D.; McLaughlin, W. H.; Milius, R. A.; Weichselbaum, R. R.; Adelstein, S. J. Estrogen receptor-mediated cytotoxicity using iodine-125. J. Cell. Biochem. 1983, 21, 39-45.
20. 125I]iodotamoxifen cytotoxicity in cultured human (MCF-7) breast cancer cells. J. Steroid Biochem. 1989, 33, 515-519.
21. 125I]iodoestradiol in cultured MCF-7 human breast cancer cells. J. Natl. Cancer Inst. 1989, 81, 437-440.
22. 125I]iodovinyl-11-beta- methoxyestradiol in MCF-7 human breast cancer cells. J. Steroid Biochem. Mol. Biol. 1991, 39, 729-734.
23. 125I]iodo-17 beta-estradiol. J. Cancer Res Clin. Oncol. 1993, 119, 207-214.
24. (b) DeSombre, E. R.; Mease, R. C.; Hughes, A.; Harper, P. V.; DeJesus, O. T.; Friedman, A. M. Bromine-80m-labeled estrogens: Auger electron-emitting, estrogen receptor-directed ligands with potential for therapy of estrogen receptor-positive cancers. Cancer Res. 1988, 48, 899-906.
25. (c) DeSombre, E. R.; Shafii, B.; Hanson, R. N.; Kuivanen, P. C.; Hughes, A. Estrogen receptor-directed radiotoxicity with Auger electrons: specificity and mean lethal dose. Cancer Res. 1992, 52, 5752-5758.
26. (a) Schwartz, J. L.; Mustafi, R.; Hughes, A.; DeSombre, E. R. DNA and chromosome breaks induced by iodine-123-labeled estrogen in Chinese hamster ovary cells. Radiat. Res. 1996, 46, 151-158.
27. (b) DeSombre, E. R.; Hughes, A.; Landel, C. C.; Greene, G.; Hanson, R.; Schwartz, J. L. Cellular and subcellular studies of the radiation effects of AuEcr electron-emitting estrogens. Acta Oncol. 1996, 35, 833-840.
28. Kassis, A. I.; Adelstein, S. J.; Haydock, C.; Sastry, K. S. R.; McElvany, K. D.; Welch, M. J. Lethality of Auger electrons from the decay of hromine-77 in the DNA of mammalian cells. Radiat. Res. 1982, 90, 362-373.
29. (a) Ganz, P. A.; Korenman, S. G. The Clinical Value of Steroid Receptors in Breast Cancer. In Cancer Diagnosis: New Concepts and Techniques: Steckle, R. J., Kagan, A. R., Eds.; Grune & Stratton: New York, 1982; pp 32-61.
30. (b) Sledge, G. W., Jr.: McGuire, W. L. Steroid Hormone Receptors in Human Breast Cancer. Adv. Cancer Res. 1983, 38, 61-75.
31. (c) Horowitz, K. B. The Structure and Function of Progesterone Receptors in Breast Cancer. J. Steroid Biochem. 1987, 27, 447-457.
32. (d) McGuire, W. L. Steroid Hormone Receptors and Disease: Breast Cancer. Proc. Soc. Exp. Biol. Med. 1979, 162, 22-25.
33. (e) Gelbfish, G. A.; Davison, A. L.; Kopel, S.; Schreibmen, B.; Gelbfish, J. S.; Degenshein, G. A.; Herz, E. L.; Cunningham, J. N. Relationship of Estrogen and Progesterone Receptors to Prognosis in Breast Cancer. Ann. Surg. 1988, 207, 75-79.
34. Furr, B. J. A.; Jordan, V. C. The Pharmacology and Clinical Uses of Tamoxifen. Pharmacol. Ther. 1984, 25, 127.
35. (a) Noguchi, S.; Miyauchi, K.; Nishizawa, Y.; Koyama, H. Induction of Progesterone Receptor with Tamoxifen in Human Breast Cancer with Special Reference to its Behavior over Time. Cancer 1988, 61, 1345-1349.
36. (b) Howell, A.; Harland, R. N. L.; Barnes, D. M.; Baildam, A. D.; Wilkinson, M. J. S.; Hayward, E.; Swindell, R.; Sellwood, R. A. Endocrine Therapy for Advanced Carcinoma of the Breast: Relationship Between the Effect of Tamoxifen upon Concentrations of Progesterone Receptor and Subsequent Response to Treatment. Cancer Res. 1987, 47, 300-304.
37. (c) Namer, M.; Lalanne, C.; Baulieu, E. Increase of Progesterone Receptor by Tamoxifen as a Hormonal Challenge Test in Breast Cancer. Cancer Res. 1980, 40, 1750.
38. (a) Buckman, B. O.; Bonasera, T. A.; Kirschbaum, K. S.; Welch, M. J.; Katzenellenbogen, J. A. Fluorine-18-labeled progestin 16α, 17α-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity. J. Med. Chem. 1995, 38, 328-337.
39. 18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations. Nucl. Med. Biol. 1994, 7, 941-952.
40. Vijaykumar, D.; Wang, M.; Kirschbaum, K. S.; Katzenellenbogen, J. A. An Efficient Route for the Preparation of a 21-Fluoro Progestin-16α, 17α-Dioxolane, a High-Affinity Ligand for PET Imaging of the Progesterone Receptor. J. Org. Chem. 2002, 67, 4904-4910.
41. Leung, S. L.; Karunanithy, R.; Becket, G.; Yeo, S. H. Norethisterone and levonorgestrel esters: a novel synthetic method. Steroids 1985, 46, 639-647.
42. Ishihara, K.; Kubota, M.; Kurihara, H.; Yamamoto, H. Scandium Trifluoromethanesulfonate as an Extremely Active Acylation Catalyst. J. Am. Chem. Soc. 1995, 117, 4413-4414.
43. Ishihara, K.; Karumi, Y.; Kubota, M.; Yamamoto, H. Scandium Trifluoromethanesulfonimide and Scandium Trifluoromethanesulfonate as Extremely Active Acetalization Catalysts. Synlett. 1996, 117, 839-841.
44. (a) Fried, J.; Sabo, E. F. The Stereochemistry of Unsymmetrically Substituted 16α, 17α -Methylenediolyprogesterones. In Hormonal Steroids, Biochemistry, Pharmacology and Therapeutics: Proceedings of the First International Congress on Hormonnl Steroids; Academic Press: New York, 1965; Vol. 2, pp 15-21.
45. (b) Fried, J.; Sabo, E. F.; Grabowich, P.; Lerner, L. J.; Kessler, W. B.; Brennan, D. M.; Borman, A. Progestationally Active Acetals and Ketals of 16α,17α -Dihydroxyprogesterone. Chem. Ind. 1961, 465-466.
46. Kochanny, M. J.; VanBrocklin, H. F.; Kym, P. R.; Carlson, K. E.; O'Neil, J. P.; Bonasera, T. A.; Welch, M. J.; Katzenellenbogen, J. A. Fluorine-18 labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors. J. Med. Chem. 1993, 36, 1120-1127.
47. Kym, P. R.; Carlson, K. E.; Katzenellenbogen, J. A. Progestin 16α,17α-dioxolane ketals as molecular probes for the progesterone receptor: synthesis, binding affinity, and photochemical evaluation. J. Med. Chem. 1993, 36, 1111-1119.
48. Yin, J.; Zarkowsky, D. S.; Thomas, D. W.; Zhao, M. M.; Huffman, M. A. Direct and convenient conversion of alcohols to fluorides. Org. Lett. 2004, 6, 1465-1468.
49. (a) Brandes, S. J.; Katzenellenbogen, J. A. Fluorinated androgens and progestins: molecular probes for androgen and progesterone receptors with potential use in positron emission tomography. Mol. Pharmacol. 1987, 32, 391-403.
50. (b) Katzenellenbogen, J. A.; Johnson, H. J., Jr.; Myers, H. N. Photoaffinity labels for estrogen binding proteins of rat uterus. Biochem. 1973, 12, 4085-4092.
51. (c) Carlson K. E.; Choi I.; Gee A.; Katzenellenbogen J. A. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochem. 1997, 36, 14897-14905.
52. Kilbourn, M. R. Fluorine-18 Labeling of Radiopharmaceuticals; National Academy Press: Washington, DC, 1990.
53. Katzenellenbogen, J. A.; Heiman, D. F.; Carlson, K. E.; Lloyd, J. E. In vivo and in vitro Steroid Receptor Assays in the Design of Estrogen Radiophamaceuticals. In Receptor-Binding Radiotracers; Eckelman, W. C., Ed.; CRC: Boca Raton, FL, 1982; Vol. 1, pp 93-126.
54. D'Auria, M.; Mauriello, G.; Bis(trifluoroacetoxy)iodobenzene-iodine system: an efficient and selective reagent for iodination of thiophene derivatives. Tetrahedron Lett. 1995, 36, 4883-4884.
55. Markl, G.; Knott, Th.; Kreitmeier, P.; Burgemeister, Th.; Kastnermaerkl, F.; Zur Moleküldynamik isomerer antiaromatischer [28]- tetraoxaporphyrinogene (6.0.6.0)-isomere [26]tetraoxaporphyrin-(6.0.6.0) dikationen, Tetrahedron 1996, 52, 11763-11782.